Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter October 30, 2019

Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports

Valentina Grossi EMAIL logo , Maria Infantino , Mariangela Manfredi , Umberto Basile ORCID logo EMAIL logo , Francesca Gulli , Mariapaola Marino , Francesca Li Gobbi , Arianna Damiani , Fabiola Atzeni and Maurizio Benucci
  1. Compliance with ethical standards: The Institutional Review Board and Health Director of San Giovanni di Dio Hospital in Florence reviewed and approved this study, and the use of everyday clinical and laboratory data for clinical and scientific studies and publications, in accordance with privacy laws. The aliquots of serum were taken off from the samples for routine diagnostic purposes as requested by the attending physicians.

  2. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  3. Research funding: None declared.

  4. Employment or leadership: None declared.

  5. Honorarium: None declared.

  6. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol 2017;13:707–18.10.1038/nrrheum.2017.187Search in Google Scholar PubMed

2. Quistrebert J, Hässler S, Bachelet D, Mbogning C, Musters A, Tak PP, et al. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: a European retrospective multicohort analysis. Semin Arthritis Rheum 2019;48:967–75.10.1016/j.semarthrit.2018.10.006Search in Google Scholar PubMed

3. Spinelli FR, Valesini G. Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases. Clin Exp Rheumatol 2013;31:954–63.Search in Google Scholar

4. Grossi V, Gulli F, Infantino M, Stefanile A, Napodano C, Benucci M, et al. The laboratory role in anti-TNF biological therapy era. Immunol Invest 2019;12:1–16.10.1080/08820139.2019.1637434Search in Google Scholar PubMed

5. Wagner CL, Schantz A, Barnathan E, Olson A, Mascelli MA, Ford J, et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003;112:37–53.Search in Google Scholar

6. Plasencia C, Pascual-Salcedo D, García-Carazo S, Lojo L, Nuño L, Villalba A, et al. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res Ther 2013;15:R79.10.1186/ar4258Search in Google Scholar PubMed PubMed Central

7. Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011;70:284–8.10.1136/ard.2010.135111Search in Google Scholar PubMed

8. Dingman R, Balu-Iyer SV. Immunogenicity of protein pharmaceuticals. J Pharm Sci 2019;108:1637–54.10.1016/j.xphs.2018.12.014Search in Google Scholar PubMed PubMed Central

9. Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol 2014;11:99–109.10.3109/1547691X.2013.821564Search in Google Scholar PubMed PubMed Central

Received: 2019-09-09
Accepted: 2019-10-03
Published Online: 2019-10-30
Published in Print: 2020-03-26

©2020 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 8.12.2022 from https://www.degruyter.com/document/doi/10.1515/cclm-2019-0950/html
Scroll Up Arrow